Effect of spironolactone on patients with atrial fibrillation and structural heart disease

Ryan S. Williams, James A de Lemos, Vassilis Dimas, Joan S Reisch, Joseph A Hill, R. Haris Naseem

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: Several studies have shown that the modulation of fibrotic scar in cardiac diseases has beneficial effects on cardiac arrhythmias. In addition, recent reports suggest a potential role of mineralocorticoid receptor upregulation in atrial fibrillation (AF). The role of spironolactone, a mineralocorticoid receptor blocker and a potent antifibrotic agent, in AF is as yet unexplored. The aim of this study was to determine if spironolactone, a mineralocorticoid receptor blocker with potent antifibrotic properties, has beneficial effects on AF. Hypothesis: Spironolactone therapy in patients with atrial fibrillation provides additional clinical benefits in addition to the current conventional pharmacological agents. Methods: A comprehensive retrospective analysis was performed on 83 patients with AF, including 23 who were treated with spironolactone for ≥3 months. The combined primary outcome of hospitalization for AF or direct current cardioversion (DCCV) was compared between patients treated with spironolactone in addition to the usual care for AF and those receiving conventional medical therapy alone. Results: Patients receiving spironolactone had significantly fewer primary outcome events (AF-related hospitalizations or DCCV) (22% vs 53%, P = 0.027). Conclusions: Spironolactone therapy is associated with a reduction in the burden of AF, as reflected by a combination of hospitalizations for AF and DCCV. Larger randomized controlled studies should be performed to evaluate the efficacy and safety of spironolactone as an adjunctive therapy for patients with AF.

Original languageEnglish (US)
Pages (from-to)415-419
Number of pages5
JournalClinical Cardiology
Volume34
Issue number7
DOIs
StatePublished - Jul 2011

Fingerprint

Spironolactone
Atrial Fibrillation
Heart Diseases
Mineralocorticoid Receptors
Electric Countershock
Hospitalization
Therapeutics
Cicatrix
Cardiac Arrhythmias
Up-Regulation
Pharmacology

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of spironolactone on patients with atrial fibrillation and structural heart disease. / Williams, Ryan S.; de Lemos, James A; Dimas, Vassilis; Reisch, Joan S; Hill, Joseph A; Naseem, R. Haris.

In: Clinical Cardiology, Vol. 34, No. 7, 07.2011, p. 415-419.

Research output: Contribution to journalArticle

@article{f54418af17f045b2b267518810b72976,
title = "Effect of spironolactone on patients with atrial fibrillation and structural heart disease",
abstract = "Background: Several studies have shown that the modulation of fibrotic scar in cardiac diseases has beneficial effects on cardiac arrhythmias. In addition, recent reports suggest a potential role of mineralocorticoid receptor upregulation in atrial fibrillation (AF). The role of spironolactone, a mineralocorticoid receptor blocker and a potent antifibrotic agent, in AF is as yet unexplored. The aim of this study was to determine if spironolactone, a mineralocorticoid receptor blocker with potent antifibrotic properties, has beneficial effects on AF. Hypothesis: Spironolactone therapy in patients with atrial fibrillation provides additional clinical benefits in addition to the current conventional pharmacological agents. Methods: A comprehensive retrospective analysis was performed on 83 patients with AF, including 23 who were treated with spironolactone for ≥3 months. The combined primary outcome of hospitalization for AF or direct current cardioversion (DCCV) was compared between patients treated with spironolactone in addition to the usual care for AF and those receiving conventional medical therapy alone. Results: Patients receiving spironolactone had significantly fewer primary outcome events (AF-related hospitalizations or DCCV) (22{\%} vs 53{\%}, P = 0.027). Conclusions: Spironolactone therapy is associated with a reduction in the burden of AF, as reflected by a combination of hospitalizations for AF and DCCV. Larger randomized controlled studies should be performed to evaluate the efficacy and safety of spironolactone as an adjunctive therapy for patients with AF.",
author = "Williams, {Ryan S.} and {de Lemos}, {James A} and Vassilis Dimas and Reisch, {Joan S} and Hill, {Joseph A} and Naseem, {R. Haris}",
year = "2011",
month = "7",
doi = "10.1002/clc.20914",
language = "English (US)",
volume = "34",
pages = "415--419",
journal = "Clinical Cardiology",
issn = "0160-9289",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Effect of spironolactone on patients with atrial fibrillation and structural heart disease

AU - Williams, Ryan S.

AU - de Lemos, James A

AU - Dimas, Vassilis

AU - Reisch, Joan S

AU - Hill, Joseph A

AU - Naseem, R. Haris

PY - 2011/7

Y1 - 2011/7

N2 - Background: Several studies have shown that the modulation of fibrotic scar in cardiac diseases has beneficial effects on cardiac arrhythmias. In addition, recent reports suggest a potential role of mineralocorticoid receptor upregulation in atrial fibrillation (AF). The role of spironolactone, a mineralocorticoid receptor blocker and a potent antifibrotic agent, in AF is as yet unexplored. The aim of this study was to determine if spironolactone, a mineralocorticoid receptor blocker with potent antifibrotic properties, has beneficial effects on AF. Hypothesis: Spironolactone therapy in patients with atrial fibrillation provides additional clinical benefits in addition to the current conventional pharmacological agents. Methods: A comprehensive retrospective analysis was performed on 83 patients with AF, including 23 who were treated with spironolactone for ≥3 months. The combined primary outcome of hospitalization for AF or direct current cardioversion (DCCV) was compared between patients treated with spironolactone in addition to the usual care for AF and those receiving conventional medical therapy alone. Results: Patients receiving spironolactone had significantly fewer primary outcome events (AF-related hospitalizations or DCCV) (22% vs 53%, P = 0.027). Conclusions: Spironolactone therapy is associated with a reduction in the burden of AF, as reflected by a combination of hospitalizations for AF and DCCV. Larger randomized controlled studies should be performed to evaluate the efficacy and safety of spironolactone as an adjunctive therapy for patients with AF.

AB - Background: Several studies have shown that the modulation of fibrotic scar in cardiac diseases has beneficial effects on cardiac arrhythmias. In addition, recent reports suggest a potential role of mineralocorticoid receptor upregulation in atrial fibrillation (AF). The role of spironolactone, a mineralocorticoid receptor blocker and a potent antifibrotic agent, in AF is as yet unexplored. The aim of this study was to determine if spironolactone, a mineralocorticoid receptor blocker with potent antifibrotic properties, has beneficial effects on AF. Hypothesis: Spironolactone therapy in patients with atrial fibrillation provides additional clinical benefits in addition to the current conventional pharmacological agents. Methods: A comprehensive retrospective analysis was performed on 83 patients with AF, including 23 who were treated with spironolactone for ≥3 months. The combined primary outcome of hospitalization for AF or direct current cardioversion (DCCV) was compared between patients treated with spironolactone in addition to the usual care for AF and those receiving conventional medical therapy alone. Results: Patients receiving spironolactone had significantly fewer primary outcome events (AF-related hospitalizations or DCCV) (22% vs 53%, P = 0.027). Conclusions: Spironolactone therapy is associated with a reduction in the burden of AF, as reflected by a combination of hospitalizations for AF and DCCV. Larger randomized controlled studies should be performed to evaluate the efficacy and safety of spironolactone as an adjunctive therapy for patients with AF.

UR - http://www.scopus.com/inward/record.url?scp=79960437223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960437223&partnerID=8YFLogxK

U2 - 10.1002/clc.20914

DO - 10.1002/clc.20914

M3 - Article

C2 - 21674535

AN - SCOPUS:79960437223

VL - 34

SP - 415

EP - 419

JO - Clinical Cardiology

JF - Clinical Cardiology

SN - 0160-9289

IS - 7

ER -